Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132074) titled 'Camrelizumab (a PD-1 inhibitor) in Combination with S-1 or Capecitabine for Adjuvant Therapy Following Curative Surgery for Biliary Tract Cancer (BTC) with High-Risk Factors: A Single-Center, Phase II Exploratory Clinical Study' on Sept. 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Condition:
Biliary Tract Cancer
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-14
Target Sample Size: Experimental Group:43;
Countries of Recruitment:
C...